Journal article
Systematic review of incretin therapy during peri-operative and intensive care
AH Hulst, MP Plummer, MW Hollmann, JH Devries, B Preckel, AM Deane, J Hermanides
Critical Care | BMC | Published : 2018
Abstract
Background: Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones. By lowering blood glucose in a glucose-dependent manner, incretin-based therapies represent a novel and promising intervention to treat hyperglycaemia in hospital settings. We performed a systematic review of the literature for all current applications of incretin-based therapies in the peri-operative and critical care settings. Methods: We searched MEDLINE, the Cochrane Library, and Embase databases for all randomised controlled trials using exogenous GLP-1, GLP-1 receptor agonists, exogenous GIP and dipeptidyl peptidase IV inhibitors in the setting of adult peri-operative c..
View full abstract